<DOC>
	<DOCNO>NCT01582854</DOCNO>
	<brief_summary>The aim trial provide evidence Actovegin symptomatic effect subject post stroke cognitive impairment ( PSCI ) six month treatment period compare subject administer placebo . Subjects receive IV infusion whilst hospital , tablet discharge . Subjects follow six month treatment stop explore cognitive symptom subject treat Actovegin show sustained improvement . The trial also explore possible prevention dementia Actovegin patient suffer recent ischaemic stroke , well effect Actovegin stroke outcome . Safety information Actovegin collect .</brief_summary>
	<brief_title>Efficacy Safety Actovegin Post-stroke Cognitive Impairment ( PSCI )</brief_title>
	<detailed_description>The drug test study call actovegin . Actovegin test treat people post stroke cognitive impairment . This study look improvement cognitive symptom people take actovegin compare placebo . The study enrol 503 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study : - Actovegin-2000 mg intravenous solution ; 2- 200 mg tablet 3 time day - Placebo intravenous solution ; tablet ( dummy inactive ) - solution tablet look like study drug active ingredient All participant receive daily intravenous infusion hospital ( maximum 20 infusion ) follow 2-200 mg tablet three time day remainder 6-month treatment period . This multi-centre trial conduct Belarus , Kazakhstan Russia . The overall time participate study 12 month . Participants make multiple visit clinic plus final visit receive last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Actovegin</mesh_term>
	<criteria>Main Participant suffer recent supratentorial ischaemic stroke support computed tomography ( CT ) scan magnetic resonance imaging ( MRI ) finding ( accordance local practice ) . Participant male female , age 60 year . Participant score National Institute Health Stroke Scale ( NIHSS ) 3 18 ( inclusive ) . Participant capable complete Montreal Cognitive Assessment ( MoCA ) score ≤ 25 point adjustment level education ( 49 school year ≤ 23 point , 1012 year ≤ 24 point , &gt; 12 year ≤ 25 point ) . Main Participant medical history dementia . Participant known medical history major depression psychotic disorder . Participant indicate treatment thrombolytic carotid surgery current standard care . Randomisation Criteria : Inclusion Criteria . Ability perform Alzheimer 's Disease Assessment Scale + Cognitive Subscale Extended Version ( ADAScog+ ) . Exclusion Criteria . Clinically suspicion progressive stroke .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Post-Stroke Cognitive Impairment ( PSCI )</keyword>
	<keyword>Stroke</keyword>
	<keyword>Actovegin</keyword>
	<keyword>Cognition disorder</keyword>
</DOC>